Patent classifications
C12N2795/00031
Methods for Detecting Microorganisms Using Microorganism Detection Protein and Other Applications of Cell Binding Components
Disclosed herein are methods and systems for rapid detection of microorganisms using a cell binding component (CBC). The specificity of CBSs for binding microorganisms allows targeted and highly specific detection of a microorganism of interest.
NOVEL BACTERIOPHAGE HAVING ABILITY TO SPECIFICALLY KILL CLOSTRIDIUM PERFRINGENS AND ANTIBACTERIAL COMPOSITION COMPRISING THE SAME
The present disclosure relates to a novel bacteriophage having ability to specifically kill Clostridium perfringens and an antibacterial composition comprising the same. The novel bacteriophage CJ_CP_20-25 has the effect of specifically killing Clostridium perfringens, exhibits excellent acid resistance and heat resistance, and can thus be widely used in antibiotics, feed additives, drinking water additives, feed, drinking water, disinfectants, or cleaning agents for the prevention or treatment of infectious diseases caused by Clostridium perfringens.
Bacteriophage and methods of making and using
Bacteriophage are provided, and methods of making and using the bacteriophage also are provided. The bacteriophage can be provided in a tobacco product, where the bacteriophage reduces the number of viable bacteria in the tobacco product and includes a nucleic acid sequence encoding an endolysin having at least 95% sequence identity to the nucleic acid sequence shown in SEQ ID NO: 1 or to the amino acid sequence shown in SEQ ID NO: 2.
Endolysin from bacteriophage against Geobacillus and methods of using
Bacteriophage against Geobacillus are provided, and methods of making and using the bacteriophage also are provided.
Methods and Systems for the Rapid Detection of Salmonella Using Infectious Agents
Disclosed herein are methods and systems for rapid detection of microorganisms in a sample. A genetically modified bacteriophage is also disclosed which comprises an indicator gene in the late gene region. The specificity of the bacteriophage, such as Salmonella-specific bacteriophage, allows detection of a specific microorganism, such as Salmonella spp. and an indicator signal may be amplified to optimize assay sensitivity.
Methods and Systems for the Rapid Detection of Cronobacter Using Infectious Agents
Disclosed herein are methods and systems for rapid detection of microorganisms such as Cronobacter spp. in a sample. A genetically modified bacteriophage is also disclosed which comprises an indicator gene in the late gene region. The specificity of the bacteriophage, such as Cronobacter-specific bacteriophage, allows detection of a specific microorganism, such as Cronobacter spp. and an indicator signal may be amplified to optimize assay sensitivity.
Compositions for in vivo expression of therapeutic sequences in the microbiome
Compositions for a phage particle are disclosed. The phage particle is non-replicating and includes at least one heterologous nucleic acid sequence that is capable of being expressed in a target bacteria. The expressed heterologous nucleic acid sequence is non-lethal to the target bacteria.
Bacteriophage and Methods of Making and Using
Bacteriophage are provided, and methods of making and using the bacteriophage also are provided.
Antibacterial and protective bacteriophage formulations and methods for making and using them
Provided are compositions and methods for treating, ameliorating and preventing infections, disorders and conditions in mammals, including genetically-predisposed and chronic disorders, where a microbial or bacterial flora is at least one causative or symptom-producing factor. Provided are compositions and methods used to treat, prevent or ameliorate an infection, for example, an infection in the gastrointestinal tract, or bowel. Provided are compositions and methods for treating, ameliorating and/or preventing a condition comprising an abnormal, disrupted or pathological mucosal surface or mucus-covered epithelium, or a condition caused, modified or effected by an abnormal, disrupted or pathological microbiotia, wherein optionally the infection or condition comprises a diarrhea, a colitis, obesity, diabetes, autism, a cystic fibrosis, a dysentery, a gastrointestinal infection, a gastrointestinal inflammation, a gastrointestinal dysbiosis, a gastrointestinal upset, a lung infection, a bacterial infection, a viral infection, a secondary infection, an inflammation, a mucus hypersecretion, or a dysbiosis.
NOVEL METHODS FOR QUANTIFYING PROTEINS USING PHAGE-BASED SEQUENCING
The present invention provides methods of identifying the presence and relative abundance of a protein in or on a cell or population of cells, with the methods comprising applying to a population of cellular proteins a collection of Fab-phage particles that contain nucleic acid encoding at least one antibody Fab fragment, wherein each of the antibody Fab fragments has a known protein to which it will bind in a specific manner. After binding is allowed to occur, those Fab-phage not bound to targets are washed away and the remaining phage are propagated in bacteria before the nucleic acid within the Fab-phage is amplified and then sequenced to determine the polynucleotide sequences of the nucleic acid molecules from the Fab-phages that bound to the cellular proteins. The nucleotide sequences of the nucleic acid molecules from the Fab-phages correlate to the coding sequences of the antibody Fab fragments that are known to bind in a specific manner to a protein.